Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Galantamine
Overview
What is Galantamine?
Galantamine hydrobromide, USP is a reversible, competitive acetylcholinesterase inhibitor. It is known chemically as (4a,6,8a)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6-benzofuro[3a,3,2-][2]benzazepin-6-ol hydrobromide. It has a molecular formula of CHNO •HBr and a molecular weight of 368.27. Galantamine hydrobromide is a white to off-white powder and is sparingly soluble in water. The structural formula for galantamine hydrobromide is:
Galantamine tablets for oral use are available in blue film-coated, round tablets of 4 mg, 8 mg or 12 mg. Each 4 mg, 8 mg and 12 mg (base equivalent) tablet contains 5.126 mg, 10.253 mg and 15.379 mg of galantamine hydrobromide, respectively. Inactive ingredients include colloidal silicon dioxide, FD&C Blue No. 2 Aluminum Lake, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium lauryl sulfate, sodium starch glycolate, titanium dioxide and triacetin.
What does Galantamine look like?
What are the available doses of Galantamine?
Sorry No records found.
What should I talk to my health care provider before I take Galantamine?
Sorry No records found
How should I use Galantamine?
Galantamine tablets are indicated for the treatment of mild to moderate dementia of the Alzheimer's type.
The dosage of galantamine tablets shown to be effective in controlled clinical trials is 16 to 32 mg/day given as twice daily dosing. As the dose of 32 mg/day is less well tolerated than lower doses and does not provide increased effectiveness, the recommended dose range is 16 to 24 mg/day given in a BID regimen. The dose of 24 mg/day did not provide a statistically significant greater clinical benefit than 16 mg/day. It is possible, however, that a daily dose of 24 mg of galantamine tablets might provide additional benefit for some patients.
The recommended starting dose of galantamine tablets is 4 mg twice a day (8 mg/day). The dose should be increased to the initial maintenance dose of 8 mg twice a day (16 mg/day) after a minimum of 4 weeks. A further increase to 12 mg twice a day (24 mg/day) should be attempted after a minimum of 4 weeks at 8 mg twice a day (16 mg/day). Dose increases should be based upon assessment of clinical benefit and tolerability of the previous dose.
Galantamine tablets should be administered twice a day, preferably with morning and evening meals.
Patients and caregivers should be advised to ensure adequate fluid intake during treatment. If therapy has been interrupted for several days or longer, the patient should be restarted at the lowest dose and the dose escalated to the current dose.
The abrupt withdrawal of galantamine tablets in those patients who had been receiving doses in the effective range was not associated with an increased frequency of adverse events in comparison with those continuing to receive the same doses of that drug. The beneficial effects of galantamine tablets are lost, however, when the drug is discontinued.
What interacts with Galantamine?
Galantamine tablets are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation.
What are the warnings of Galantamine?
Anesthesia
Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia.
Cardiovascular Conditions
Because of their pharmacological action, cholinesterase inhibitors have vagotonic effects on the sinoatrial and atrioventricular nodes, leading to bradycardia and AV block. These actions may be particularly important to patients with supraventricular cardiac conduction disorders or to patients taking other drugs concomitantly that significantly slow heart rate. Post-marketing surveillance of marketed anticholinesterase inhibitors has shown, however, that bradycardia and all types of heart block have been reported in patients both with and without known underlying cardiac conduction abnormalities. Therefore all patients should be considered at risk for adverse effects on cardiac conduction.
In randomized controlled trials, bradycardia was reported more frequently in galantamine-treated patients than in placebo-treated patients, but was rarely severe and rarely led to treatment discontinuation. The overall frequency of this event was 2% to 3% for galantamine doses up to 24 mg/day compared with < 1% for placebo. No increased incidence of heart block was observed at the recommended doses.
Patients treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose related increase in risk of syncope (placebo 0.7% [2/286]; 4 mg BID 0.4% [3/692]; 8 mg BID 1.3% [7/552]; 12 mg BID 2.2% [6/273]).
Gastrointestinal Conditions
Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). Clinical studies of galantamine hydrobromide have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding.
Galantamine as a predictable consequence of its pharmacological properties, has been shown to produce nausea, vomiting, diarrhea, anorexia, and weight loss (see ).
Genitourinary
Although this was not observed in clinical trials with galantamine, cholinomimetics may cause bladder outflow obstruction.
Neurological Conditions
Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. However, seizure activity may also be a manifestation of Alzheimer's disease. In clinical trials, there was no increase in the incidence of convulsions with galantamine compared to placebo.
Pulmonary Conditions
Because of its cholinomimetic action, galantamine should be prescribed with care to patients with a history of severe asthma or obstructive pulmonary disease.
What are the precautions of Galantamine?
Information for Patients and Caregivers
Caregivers should be instructed about the recommended dosage and administration of galantamine tablets. Galantamine tablets should be administered twice per day, preferably with the morning and evening meals. Dose escalation (dose increases) should follow a minimum of 4 weeks at prior dose.
Patients and caregivers should be advised that the most frequent adverse events associated with use of the drug can be minimized by following the recommended dosage and administration.
Patients and caregivers should be advised to ensure adequate fluid intake during treatment. If therapy has been interrupted for several days or longer, the patient should be restarted at the lowest dose and the dose escalated to the current dose.
Death in Subjects with Mild Cognitive Impairment (MCI)
In two randomized placebo controlled trials of 2 years duration in subjects with mild cognitive impairment (MCI), a total of 13 subjects on galantamine (n = 1,026) and one subject on placebo (n = 1,022) died. The deaths were due to various causes which could be expected in an elderly population; about half of the galantamine deaths appeared to result from various vascular causes (myocardial infarction, stroke, and sudden death).
Although the difference in mortality between galantamine and placebo-treated groups in these two studies was significant, the results are highly discrepant with other studies of galantamine. Specifically, in these two MCI studies, the mortality rate in the placebo-treated subjects was markedly lower than the rate in placebo-treated patients in trials of galantamine in Alzheimer's disease or other dementias (0.7 per 1,000 persons years compared to 22 to 61 per 1,000 person years, respectively). Although the mortality rate in the galantamine-treated MCI subjects was also lower than that observed in galantamine-treated patients in Alzheimer's disease and other dementia trials (10.2 per 1,000 person years compared to 23 to 31 per 1,000 person years, respectively), the relative difference was much less. When the Alzheimer's disease and other dementia studies were pooled (n = 6,000), the mortality rate in the placebo group numerically exceeded that in the galantamine group. Furthermore, in the MCI studies, no subjects in the placebo group died after 6 months, a highly unexpected finding in this population.
Individuals with mild cognitive impairment demonstrate isolated memory greater than expected for their age and education, but do not meet current diagnostic criteria for Alzheimer's disease.
Special Populations
In patients with moderately impaired hepatic function, dose titration should proceed cautiously (see and ). The use of galantamine in patients with severe hepatic impairment is not recommended.
In patients with moderately impaired renal function, dose titration should proceed cautiously (see and ). In patients with severely impaired renal function (CL < 9 mL/min) the use of galantamine is not recommended.
Drug-Drug Interactions
(see also )
Galantamine has the potential to interfere with the activity of anticholinergic medications.
A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
Carcinogenesis, Mutagenesis and Impairment of Fertility
In a 24-month oral carcinogenicity study in rats, a slight increase in endometrial adenocarcinomas was observed at 10 mg/kg/day (4 times the Maximum Recommended Human Dose [MRHD] on a mg/m basis or 6 times on an exposure [AUC] basis) and 30 mg/kg/day (12 times MRHD on a mg/m basis or 19 times on an AUC basis). No increase in neoplastic changes was observed in females at 2.5 mg/kg/day (equivalent to the MRHD on a mg/m basis or 2 times on an AUC basis) or in males up to the highest dose tested of 30 mg/kg/day (12 times the MRHD on a mg/m and AUC basis).
Galantamine was not carcinogenic in a 6-month oral carcinogenicity study in transgenic (P 53-deficient) mice up to 20 mg/kg/day, or in a 24-month oral carcinogenicity study in male and female mice up to 10 mg/kg/day (2 times the MRHD on a mg/m basis and equivalent on an AUC basis).
Galantamine produced no evidence of genotoxic potential when evaluated in the Ames or reverse mutation assay, mouse lymphoma assay, micronucleus test in mice, or chromosome aberration assay in Chinese hamster ovary cells.
No impairment of fertility was seen in rats given up to 16 mg/kg/day (7 times the MRHD on a mg/m basis) for 14 days prior to mating in females and for 60 days prior to mating in males.
Pregnancy
Nursing Mothers
It is not known whether galantamine is excreted in human breast milk. Galantamine has no indication for use in nursing mothers.
Pediatric Use
There are no adequate and well controlled trials documenting the safety and efficacy of galantamine in any illness occurring in children. Therefore, use of galantamine in children is not recommended.
What are the side effects of Galantamine?
What should I look out for while using Galantamine?
Galantamine tablets are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation.
What might happen if I take too much Galantamine?
Because strategies for the management of overdose are continually evolving, it is advisable to contact a poison control center to determine the latest recommendations for the management of an overdose of any drug.
As in any case of overdose, general supportive measures should be utilized. Signs and symptoms of significant overdosing of galantamine are predicted to be similar to those of overdosing of other cholinomimetics. These effects generally involve the central nervous system, the parasympathetic nervous system, and the neuromuscular junction. In addition to muscle weakness or fasciculations, some or all of the following signs of cholinergic crisis may develop: severe nausea, vomiting, gastrointestinal cramping, salivation, lacrimation, urination, defecation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved.
Tertiary anticholinergics such as atropine may be used as an antidote for galantamine hydrobromide overdosage. Intravenous atropine sulfate titrated to effect is recommended at an initial dose of 0.5 mg to 1 mg i.v. with subsequent doses based upon clinical response. Atypical responses in blood pressure and heart rate have been reported with other cholinomimetics when coadministered with quaternary anticholinergics. It is not known whether galantamine and/or its metabolites can be removed by dialysis (hemodialysis, peritoneal dialysis, or hemofiltration). Dose related signs of toxicity in animals included hypoactivity, tremors, clonic convulsions, salivation, lacrimation, chromodacryorrhea, mucoid feces, and dyspnea.
In one post-marketing report, one patient who had been taking 4 mg of galantamine daily for a week inadvertently ingested eight 4 mg tablets (32 mg total) on a single day. Subsequently, she developed bradycardia, QT prolongation, ventricular tachycardia and Torsades de pointes accompanied by a brief loss of consciousness for which she required hospital treatment. Two additional cases of accidental ingestion of 32 mg (nausea, vomiting, and dry mouth; nausea, vomiting, and substernal chest pain) and one of 40 mg (vomiting), resulted in brief hospitalizations for observation with full recovery. One patient, who was prescribed 24 mg/day and had a history of hallucinations over the previous two years, mistakenly received 24 mg twice daily for 34 days and developed hallucinations requiring hospitalization. Another patient, who was prescribed 16 mg/day of oral solution, inadvertently ingested 160 mg (40 mL) and experienced sweating, vomiting, bradycardia, and near-syncope one hour later, which necessitated hospital treatment. His symptoms resolved within 24 hours.
How should I store and handle Galantamine?
Store at 20°-25°C (68°-77°F) (see USP Controlled Room Temperature). PROTECT FROM LIGHT. KEEP TIGHTLY CLOSED. Sarafem is a registered trademark of Eli Lilly and Company. Galantamine Tablets, USP are available as 4 mg, 8 mg, or 12 mg tablets.The 4 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7541-39blisterpacks of 30 tabletsThe 8 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7542-39blisterpacks of 30 tabletsThe 12 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7543-39blisterpacks of 30 tabletsStore at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]Dispense in a tight light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505MAY 2008GLNT:R1Galantamine Tablets, USP are available as 4 mg, 8 mg, or 12 mg tablets.The 4 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7541-39blisterpacks of 30 tabletsThe 8 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7542-39blisterpacks of 30 tabletsThe 12 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7543-39blisterpacks of 30 tabletsStore at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]Dispense in a tight light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505MAY 2008GLNT:R1Galantamine Tablets, USP are available as 4 mg, 8 mg, or 12 mg tablets.The 4 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7541-39blisterpacks of 30 tabletsThe 8 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7542-39blisterpacks of 30 tabletsThe 12 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7543-39blisterpacks of 30 tabletsStore at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]Dispense in a tight light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505MAY 2008GLNT:R1Galantamine Tablets, USP are available as 4 mg, 8 mg, or 12 mg tablets.The 4 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7541-39blisterpacks of 30 tabletsThe 8 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7542-39blisterpacks of 30 tabletsThe 12 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7543-39blisterpacks of 30 tabletsStore at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]Dispense in a tight light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505MAY 2008GLNT:R1Galantamine Tablets, USP are available as 4 mg, 8 mg, or 12 mg tablets.The 4 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7541-39blisterpacks of 30 tabletsThe 8 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7542-39blisterpacks of 30 tabletsThe 12 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7543-39blisterpacks of 30 tabletsStore at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]Dispense in a tight light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505MAY 2008GLNT:R1Galantamine Tablets, USP are available as 4 mg, 8 mg, or 12 mg tablets.The 4 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7541-39blisterpacks of 30 tabletsThe 8 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7542-39blisterpacks of 30 tabletsThe 12 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7543-39blisterpacks of 30 tabletsStore at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]Dispense in a tight light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505MAY 2008GLNT:R1Galantamine Tablets, USP are available as 4 mg, 8 mg, or 12 mg tablets.The 4 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7541-39blisterpacks of 30 tabletsThe 8 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7542-39blisterpacks of 30 tabletsThe 12 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7543-39blisterpacks of 30 tabletsStore at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]Dispense in a tight light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505MAY 2008GLNT:R1Galantamine Tablets, USP are available as 4 mg, 8 mg, or 12 mg tablets.The 4 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7541-39blisterpacks of 30 tabletsThe 8 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7542-39blisterpacks of 30 tabletsThe 12 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7543-39blisterpacks of 30 tabletsStore at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]Dispense in a tight light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505MAY 2008GLNT:R1Galantamine Tablets, USP are available as 4 mg, 8 mg, or 12 mg tablets.The 4 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7541-39blisterpacks of 30 tabletsThe 8 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7542-39blisterpacks of 30 tabletsThe 12 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7543-39blisterpacks of 30 tabletsStore at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]Dispense in a tight light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505MAY 2008GLNT:R1Galantamine Tablets, USP are available as 4 mg, 8 mg, or 12 mg tablets.The 4 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7541-39blisterpacks of 30 tabletsThe 8 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7542-39blisterpacks of 30 tabletsThe 12 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7543-39blisterpacks of 30 tabletsStore at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]Dispense in a tight light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505MAY 2008GLNT:R1Galantamine Tablets, USP are available as 4 mg, 8 mg, or 12 mg tablets.The 4 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7541-39blisterpacks of 30 tabletsThe 8 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7542-39blisterpacks of 30 tabletsThe 12 mg tablet is a blue film-coated, round tablet debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0615-7543-39blisterpacks of 30 tabletsStore at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]Dispense in a tight light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505MAY 2008GLNT:R1
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Although the etiology of cognitive impairment in Alzheimer's disease (AD) is not fully understood, it has been reported that acetylcholine-producing neurons degenerate in the brains of patients with Alzheimer's disease. The degree of this cholinergic loss has been correlated with degree of cognitive impairment and density of amyloid plaques (a neuropathological hallmark of Alzheimer's disease).
Galantamine, a tertiary alkaloid, is a competitive and reversible inhibitor of acetylcholinesterase. While the precise mechanism of galantamine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this mechanism is correct, galantamine's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that galantamine alters the course of the underlying dementing process.
Non-Clinical Toxicology
Galantamine tablets are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation.The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Alcohol, in particular, has been found to exhibit additive effects of this variety.
Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination. Dose adjustments of either class of agents may be necessary.
Caregivers should be instructed about the recommended dosage and administration of galantamine tablets. Galantamine tablets should be administered twice per day, preferably with the morning and evening meals. Dose escalation (dose increases) should follow a minimum of 4 weeks at prior dose.
Patients and caregivers should be advised that the most frequent adverse events associated with use of the drug can be minimized by following the recommended dosage and administration.
Patients and caregivers should be advised to ensure adequate fluid intake during treatment. If therapy has been interrupted for several days or longer, the patient should be restarted at the lowest dose and the dose escalated to the current dose.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).